- Home
- TCMD
as 07-26-2024 4:00pm EST
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | MINNEAPOLIS |
| Market Cap: | 273.3M | IPO Year: | 2016 |
| Target Price: | $30.00 | AVG Volume (30 days): | 319.9K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.70 - $23.33 | Next Earning Date: | 08-05-2024 |
| Revenue: | $276,665,000 | Revenue Growth: | 7.38% |
| Revenue Growth (this year): | 12.6% | Revenue Growth (next year): | 12.61% |
Stock Insider Trading Activity of Tactile Systems Technology Inc. (TCMD)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Birkemeyer Elaine M. | TCMD | Chief Financial Officer | May 16 '24 | Sell | $13.68 | 3,041 | $41,589.63 | 61,295 | SEC Form 4 |
| BURKE WILLIAM W | TCMD | Director | May 8 '24 | Sell | $14.06 | 2,500 | $35,150.00 | 25,273 | SEC Form 4 |
| Burns Kristie | TCMD | Sr. VP Mktg & Clinical Affairs | May 6 '24 | Sell | $14.37 | 815 | $11,712.77 | 62,574 | SEC Form 4 |
| REUVERS DANIEL L. | TCMD | President and CEO | Feb 27 '24 | Sell | $15.60 | 4,689 | $73,148.40 | 239,423 | SEC Form 4 |
| REUVERS DANIEL L. | TCMD | President and CEO | Feb 27 '24 | Sell | $15.25 | 1,396 | $21,289.00 | 238,027 | SEC Form 4 |
| Burns Kristie | TCMD | Sr. VP Mktg & Clinical Affairs | Feb 27 '24 | Sell | $15.58 | 1,091 | $17,001.16 | 63,632 | SEC Form 4 |
| Burns Kristie | TCMD | Sr. VP Mktg & Clinical Affairs | Feb 27 '24 | Sell | $15.25 | 243 | $3,705.87 | 63,389 | SEC Form 4 |
| Burns Kristie | TCMD | Sr. VP Mktg & Clinical Affairs | Feb 23 '24 | Sell | $14.80 | 2,249 | $33,278.00 | 53,765 | SEC Form 4 |
| Burns Kristie | TCMD | Sr. VP Mktg & Clinical Affairs | Feb 23 '24 | Sell | $15.91 | 2,015 | $32,048.57 | 63,512 | SEC Form 4 |
| REUVERS DANIEL L. | TCMD | President and CEO | Feb 23 '24 | Sell | $14.85 | 5,378 | $79,852.54 | 192,321 | SEC Form 4 |
| REUVERS DANIEL L. | TCMD | President and CEO | Feb 23 '24 | Sell | $15.81 | 6,239 | $98,644.83 | 244,112 | SEC Form 4 |
Latest Tactile Systems Technology Inc. News
TCMD Breaking Stock News: Dive into TCMD Ticker-Specific Updates for Smart Investing
Simply Wall St.
12 hours ago
Tactile Systems Technology, Inc. (NASDAQ:TCMD) is largely controlled by institutional shareholders who own 73% of the company
GlobeNewswire
4 days ago
Tactile Medical to Release Second Quarter of Fiscal Year 2024 Financial Results on August 5, 2024
Simply Wall St.
a month ago
Shareholders in Tactile Systems Technology (NASDAQ:TCMD) are in the red if they invested five years ago
Business Wire
2 months ago
Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition
GlobeNewswire
2 months ago
Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus
GlobeNewswire
2 months ago
Share buy-back programme - week 23
Simply Wall St.
2 months ago
Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?
Reuters
2 months ago
Japan's service sector mood hits nearly 2-year low in May
Compare TCMD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TCMD Tactile Systems Technology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.